OSCR
Oscar Health, Inc.
OSCR has the edge over OUST overall, supported by stronger fundamentals and lower modeled downside.
OUST
Ouster, Inc.
OUST offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
OUST Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
OUST's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
OUST PE Valuation
OUST has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
OUST Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect OUST's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over OUST on earnings quality, reporting a profit while its opponent remains loss making.
OUST Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.65 | +$0.98 |
| Q2 2026 | -$0.82 | +$0.98 |
| Q1 2026 | -$0.93 | +$1.02 |
| Q4 2025 | -$1.07 | +$1.01 |
| Q3 2025 | -$1.63 | +$0.98 |
| Q2 2025 | -$1.80 | +$1.16 |
| Q1 2025 | -$1.95 | +$3.67 |
| Q4 2024 | -$2.08 | +$9.02 |
OUST is still losing money, but far less than before: $0.65 per share over the past year, against $40.12 at its worst in late 2020.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over OUST on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over OUST on profitability, with a higher operating margin.
OUST Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $59.3M | +50% |
| Q2 2026 | $54.6M | +56% |
| Q1 2026 | $48.6M | +49% |
| Q4 2025 | $62.2M | +107% |
| Q3 2025 | $39.5M | +41% |
| Q2 2025 | $35M | +30% |
| Q1 2025 | $32.6M | +26% |
| Q4 2024 | $30.1M | +23% |
OUST's revenue has grown year over year for 15 quarters in a row: $59M last quarter, up 50% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -32% | +29 points |
| Q2 2026 | -37% | +40 points |
| Q1 2026 | -40% | +34 points |
| Q4 2025 | 1.4% | +87 points |
| Q3 2025 | -61% | +37 points |
| Q2 2025 | -77% | +17 points |
| Q1 2025 | -73% | +27 points |
| Q4 2024 | -85% | +68 points |
OUST's operating margin was −32% last quarter, up 29 points from the same quarter a year ago, near the top of its range since 2019.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over OUST on cash generation, producing positive trailing cash flow while its opponent burns cash.
OUST Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$35M | -$15M |
| Q2 2026 | -$15.4M | -$13.2M |
| Q1 2026 | -$9.8M | -$4.4M |
| Q4 2025 | -$37.2M | -$33.2M |
| Q3 2025 | -$20M | -$15.7M |
| Q2 2025 | -$2.2M | +$19.8M |
| Q1 2025 | -$5.4M | +$1.7M |
| Q4 2024 | -$4M | +$20.6M |
OUST has burned cash in almost every quarter: −$97M over the past year, against −$32M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
OUST Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +8.3% | +5.5M shares |
| 1 year | +23% | +13.5M shares |
| 3 years | +82% | +32.2M shares |
| 5 years | +1183% | +65.9M shares |
| Available history | +6407% | +70.4M shares |
OUST has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | $1,000 |
| Q3 2022 | $3,000 |
| Q2 2022 | $12,000 |
| Q1 2022 | $31,000 |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
OUST Net Leverage
OUST's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
OUST Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.2 | Neutral |
| Stochastic | 26.0 | Neutral |
OUST's weekly RSI is 51 (neutral) and its Stochastic is 26 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
OUST PE vs Technology Sector
OUST has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over OUST on trend strength, trading above more of its moving averages.
OUST Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $35.9 | 1.9% above |
| 20 week MA | $38.1 | 4% below |
| 50 week MA | $31.3 | 17% above |
| 100 week MA | $24.9 | 47% above |
| 200 week MA | $16.3 | 125% above |
OUST's trend is mixed: it's above four of its five weekly moving averages, and 125% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over OUST on returns for 2026, with the stronger performance.
OUST Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $97.0 | $162.5 | +68% |
| 2021 | $162.5 | $53.8 | -67% |
| 2022 | $53.8 | $8.88 | -83% |
| 2023 | $8.88 | $7.67 | -14% |
| 2024 | $7.67 | $12.5 | +63% |
| 2025 | $12.5 | $22.0 | +76% |
| 2026 YTD | $22.0 | $36.6 | +67% |
OUST is up 67% so far in 2026, after finishing lower in three of the previous six years.